News

  • 10 November 2011

    Merck hit by double FDA rejection

    US-based pharmaceutical company Merck has been hit by a double rejection from the US Food and Drug Administration, the company confirmed through a regulatory filing with the US Securities and...

  • 9 November 2011

    UCB reports RAPID 1 post-hoc data of Cimzia

    UCB, a Belgium-based biopharmaceutical company, has announced the results from a Phase III double-blind placebo-controlled RAPID 1 post-hoc analysis designed to evaluate the efficacy and tolerability of Cimzia (certolizumab pegol)...

  • 8 November 2011

    Abbott announces results of Humira trials

    Abbott has announced the data from Premier and DE019 Phase III studies that investigated Humira (adalimumab) plus methotrexate for up to eight years in patients with early moderate to severe...

Close
Close
Close

Go Top